Immune checkpoint inhibitors for the treatment of MSI-H/MMR-D colorectal cancer and a perspective on resistance mechanisms
2019 · British Journal of Cancer · 398 citations
https://doi.org/10.1038/s41416-019-0599-y
G
Gregory B. Lesinski
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
463
Papers
8.2K
Citations
52
h-index
118
i10-index
Gregory B. Lesinski is an academic researcher. The author has contributed to research in topics: Cancer Immunotherapy and Biomarkers & Pancreatic and Hepatic Oncology Research & CAR-T cell therapy research. The author has an h-index of 52, co-authored 394 publications.
ORCID: 0000-0002-8787-7678Papers by this author
worksA novel small molecule inhibits STAT3 phosphorylation and DNA binding activity and exhibits potent growth suppressive activity in human cancer cells
2010 · Molecular Cancer · 148 citations
https://doi.org/10.1186/1476-4598-9-217
The small molecule curcumin analog FLLL32 induces apoptosis in melanoma cells via STAT3 inhibition and retains the cellular response to cytokines with anti-tumor activity
2010 · Molecular Cancer · 115 citations
https://doi.org/10.1186/1476-4598-9-165
Inhibition of Jak/STAT signaling reduces the activation of pancreatic stellate cells in vitro and limits caerulein-induced chronic pancreatitis in vivo
2017 · Scientific Reports · 83 citations
https://doi.org/10.1038/s41598-017-01973-0
Modulation of SOCS protein expression influences the interferon responsiveness of human melanoma cells
2010 · BMC Cancer · 55 citations
https://doi.org/10.1186/1471-2407-10-142
Stromal ETS2 Regulates Chemokine Production and Immune Cell Recruitment during Acinar-to-Ductal Metaplasia
2016 · Neoplasia · 34 citations
https://doi.org/10.1016/j.neo.2016.07.006
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat